PL2464382T3 - Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny - Google Patents

Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny

Info

Publication number: PL2464382T3
Authority: PL; Poland
Prior art keywords: afucosylated; bendamustine; antibody; combination therapy; therapy
Prior art date: 2009-08-14

Application number

PL10747168T

Other languages

English (en)

Inventor

Frank Herting

Christian Klein

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-08-14

Filing date

2010-08-12

Publication date

2017-09-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41351729&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2464382(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-08-12 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2017-09-29 Publication of PL2464382T3 publication Critical patent/PL2464382T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL10747168T 2009-08-14 2010-08-12 Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny PL2464382T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP09010489		2009-08-14

Publications (1)

Publication Number	Publication Date
PL2464382T3 true PL2464382T3 (pl)	2017-09-29

Family

ID=41351729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10747168T PL2464382T3 (pl)	2009-08-14	2010-08-12	Leczenie skojarzone z zastosowaniem zdefukozylowanego przeciwciała anty-CD20 i bendamustyny

Country Status (34)

Country	Link
US (4)	US20110165151A1 (pl)
EP (1)	EP2464382B1 (pl)
JP (3)	JP5646626B2 (pl)
KR (1)	KR101425736B1 (pl)
CN (2)	CN107261138A (pl)
AR (1)	AR077866A1 (pl)
AU (1)	AU2010281866B2 (pl)
CA (1)	CA2769674C (pl)
CL (1)	CL2012000391A1 (pl)
CR (1)	CR20120036A (pl)
CY (2)	CY1119251T1 (pl)
DK (1)	DK2464382T3 (pl)
ES (1)	ES2630158T3 (pl)
HK (1)	HK1245145A1 (pl)
HR (1)	HRP20170972T1 (pl)
HU (2)	HUE033531T2 (pl)
IL (1)	IL217753A (pl)
LT (2)	LT2464382T (pl)
LU (1)	LUC00045I2 (pl)
MA (1)	MA33469B1 (pl)
MX (2)	MX355849B (pl)
MY (1)	MY163003A (pl)
NO (1)	NO2017054I1 (pl)
NZ (1)	NZ597666A (pl)
PL (1)	PL2464382T3 (pl)
PT (1)	PT2464382T (pl)
RS (1)	RS56146B1 (pl)
SG (1)	SG178324A1 (pl)
SI (1)	SI2464382T1 (pl)
SM (1)	SMT201700329T1 (pl)
TW (1)	TWI409079B (pl)
UA (1)	UA110096C2 (pl)
WO (1)	WO2011018224A1 (pl)
ZA (1)	ZA201200830B (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT1692182E (pt)	2003-11-05	2010-05-13	Roche Glycart Ag	Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
ATE543835T1 (de)	2007-07-16	2012-02-15	Genentech Inc	Anti-cd79b-antikörper und immunkonjugate und anwendungsverfahren
ES2528922T3 (es)	2007-07-16	2015-02-13	Genentech, Inc.	Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
PT2247620T (pt)	2008-01-31	2016-08-23	Genentech Inc	Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
MX2012013622A (es)	2010-05-31	2013-02-01	Ono Pharmaceutical Co	Derivado de purinona.
FR2976811A1 (fr) *	2011-06-22	2012-12-28	Lfb Biotechnologies	Utilisation d'un anticorps anti-cd20 a haute adcc pour le traitement de la maladie de waldenstrom
KR102117202B1 (ko) *	2011-08-16	2020-06-01	모르포시스 아게	항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
EP2744515B1 (en) *	2011-08-16	2022-02-09	MorphoSys AG	Combination therapy with an anti-cd19 antibody and a nitrogen mustard
FR2980110A1 (fr) *	2011-09-20	2013-03-22	Lfb Biotechnologies	Combinaison d'anticorps anti-cd20 et de bendamustine
DK2786996T3 (en)	2011-11-29	2016-12-19	Ono Pharmaceutical Co	Hydrochloride PURINONDERIVAT
CN103375132A (zh) *	2012-04-24	2013-10-30	长江大学	井下旋转冲击式钻井工具
US9963513B2 (en)	2013-02-05	2018-05-08	Engmab Sàrl	Method for the selection of antibodies against BCMA
EP2762496A1 (en)	2013-02-05	2014-08-06	EngMab AG	Method for the selection of antibodies against BCMA
BR112015030457A2 (pt) *	2013-06-07	2017-08-22	Nordic Nanovector As	Método para regular positivamente a expressão de antígeno
JP6528779B2 (ja)	2014-03-25	2019-06-12	小野薬品工業株式会社	びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
DK3262071T3 (da)	2014-09-23	2020-06-15	Hoffmann La Roche	Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
JP6750613B2 (ja)	2015-04-09	2020-09-02	小野薬品工業株式会社	プリノン誘導体の製造方法
AU2016302881B2 (en)	2015-08-03	2022-09-15	Bristol-Myers Squibb Company	Monoclonal antibodies against BCMA
EP3257866A1 (en) *	2016-06-17	2017-12-20	Academisch Medisch Centrum	Modified anti-tnf antibody and use thereof in the treatment of ibd
EP3535295A1 (en)	2016-11-02	2019-09-11	EngMab Sàrl	Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
EP3551034A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en)	2017-03-30	2023-06-07	Biora Therapeutics, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
BR112020023704A2 (pt)	2018-05-23	2021-02-17	Celgene Corporation	compostos antiproliferativos e anticorpo bispecífico contra bcma e cd3 para uso combinado
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020106757A1 (en)	2018-11-19	2020-05-28	Progenity, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP7287048B2 (ja)	2019-03-27	2023-06-06	セイコーエプソン株式会社	ロボット
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置
EP4433506A1 (en)	2021-11-16	2024-09-25	Genentech, Inc.	Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5204244A (en)	1987-10-27	1993-04-20	Oncogen	Production of chimeric antibodies by homologous recombination
US5202238A (en)	1987-10-27	1993-04-13	Oncogen	Production of chimeric antibodies by homologous recombination
US5736137A (en)	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
WO1999060023A1 (en)	1998-05-15	1999-11-25	Imclone Systems Incorporated	Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
PT1176195E (pt)	1999-04-09	2013-07-18	Kyowa Hakko Kirin Co Ltd	Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
FR2807767B1 (fr)	2000-04-12	2005-01-14	Lab Francais Du Fractionnement	Anticorps monoclonaux anti-d
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
KR100988949B1 (ko)	2001-10-25	2010-10-20	제넨테크, 인크.	당단백질 조성물
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
KR20110017020A (ko)	2002-10-17	2011-02-18	젠맵 에이/에스	Ｃｄ20에 대한 인간 모노클로날 항체
EP1944320A1 (en)	2002-12-16	2008-07-16	Genentech, Inc.	Immunoglobulin variants and uses thereof
CZ308720B6 (cs)	2003-01-22	2021-03-24	Roche Glycart Ag	Fúzní konstrukty a jejich použití pro přípravu protilátek se zvýšenou vazebnou afinitou k receptorům Fc a efektorovou funkcí
JP2006528697A (ja) *	2003-05-16	2006-12-21	イデラファーマシューティカルズインコーポレイテッド	イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
EP1648511A1 (en)	2003-07-29	2006-04-26	Morphotek, Inc.	Antibodies and methods for generating genetically altered antibodies with enhanced effector function
CN1871259A (zh)	2003-08-22	2006-11-29	比奥根艾迪克Ma公司	具有改变的效应物功能的经改进的抗体和制备它的方法
AU2004273791A1 (en)	2003-09-05	2005-03-31	Genentech, Inc.	Antibodies with altered effector functions
PT1692182E (pt)	2003-11-05	2010-05-13	Roche Glycart Ag	Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
WO2005103081A2 (en)	2004-04-20	2005-11-03	Genmab A/S	Human monoclonal antibodies against cd20
WO2007024249A2 (en)	2004-11-10	2007-03-01	Macrogenics, Inc.	Engineering fc antibody regions to confer effector function
US8008443B2 (en)	2005-04-26	2011-08-30	Medimmune, Llc	Modulation of antibody effector function by hinge domain engineering
CA2605697A1 (en)	2005-04-26	2006-11-02	Bioren, Inc.	Method of producing human igg antibodies with enhanced effector functions
RU2482132C2 (ru)	2005-08-26	2013-05-20	Роше Гликарт Аг	Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
ES2417147T3 (es) *	2005-10-21	2013-08-06	Revo Biologics, Inc.	Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
US20090110688A1 (en) *	2007-10-24	2009-04-30	Georg Fertig	Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
EP2234641B1 (en) *	2008-01-03	2015-08-19	Genmab A/S	Monoclonal antibodies against cd32b
EA201170940A1 (ru) *	2009-01-16	2012-02-28	ГЛЭКСОСМИТКЛАЙН ЭлЭлСи	Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
WO2010120288A1 (en) *	2009-04-15	2010-10-21	Invista Technologies S.A R.L.	Improving miscibility of otherwise immiscible compounds

2010
- 2010-08-11 TW TW099126813A patent/TWI409079B/zh active
- 2010-08-12 KR KR1020127006528A patent/KR101425736B1/ko active Active
- 2010-08-12 NZ NZ597666A patent/NZ597666A/xx unknown
- 2010-08-12 HU HUE10747168A patent/HUE033531T2/hu unknown
- 2010-08-12 HR HRP20170972TT patent/HRP20170972T1/hr unknown
- 2010-08-12 CN CN201710422477.2A patent/CN107261138A/zh active Pending
- 2010-08-12 SG SG2012008843A patent/SG178324A1/en unknown
- 2010-08-12 AU AU2010281866A patent/AU2010281866B2/en active Active
- 2010-08-12 PL PL10747168T patent/PL2464382T3/pl unknown
- 2010-08-12 CN CN201080035971XA patent/CN102596245A/zh active Pending
- 2010-08-12 DK DK10747168.2T patent/DK2464382T3/en active
- 2010-08-12 WO PCT/EP2010/004939 patent/WO2011018224A1/en not_active Ceased
- 2010-08-12 JP JP2012524146A patent/JP5646626B2/ja active Active
- 2010-08-12 EP EP10747168.2A patent/EP2464382B1/en active Active
- 2010-08-12 CA CA2769674A patent/CA2769674C/en active Active
- 2010-08-12 LT LTEP10747168.2T patent/LT2464382T/lt unknown
- 2010-08-12 RS RS20170647A patent/RS56146B1/sr unknown
- 2010-08-12 MX MX2014015198A patent/MX355849B/es unknown
- 2010-08-12 MA MA34585A patent/MA33469B1/fr unknown
- 2010-08-12 PT PT107471682T patent/PT2464382T/pt unknown
- 2010-08-12 ES ES10747168.2T patent/ES2630158T3/es active Active
- 2010-08-12 SM SM20170329T patent/SMT201700329T1/it unknown
- 2010-08-12 MY MYPI2012000606A patent/MY163003A/en unknown
- 2010-08-12 MX MX2012001782A patent/MX2012001782A/es active IP Right Grant
- 2010-08-12 AR ARP100102968A patent/AR077866A1/es unknown
- 2010-08-12 SI SI201031491T patent/SI2464382T1/sl unknown
- 2010-08-13 US US12/855,827 patent/US20110165151A1/en not_active Abandoned
- 2010-12-08 UA UAA201202678A patent/UA110096C2/ru unknown
2012
- 2012-01-19 CR CR20120036A patent/CR20120036A/es unknown
- 2012-01-26 IL IL217753A patent/IL217753A/en active IP Right Grant
- 2012-02-02 ZA ZA2012/00830A patent/ZA201200830B/en unknown
- 2012-02-08 US US13/368,465 patent/US20120315268A1/en not_active Abandoned
- 2012-02-14 CL CL2012000391A patent/CL2012000391A1/es unknown
2013
- 2013-01-18 HK HK18104879.8A patent/HK1245145A1/zh unknown
- 2013-03-06 US US13/787,532 patent/US20140044705A1/en not_active Abandoned
2014
- 2014-05-08 US US14/273,148 patent/US20160166688A9/en not_active Abandoned
- 2014-11-04 JP JP2014224221A patent/JP5963013B2/ja active Active
2016
- 2016-06-15 JP JP2016118739A patent/JP2016222673A/ja active Pending
2017
- 2017-07-03 CY CY20171100706T patent/CY1119251T1/el unknown
- 2017-10-26 CY CY2017034C patent/CY2017034I2/el unknown
- 2017-10-26 LU LU00045C patent/LUC00045I2/fr unknown
- 2017-10-26 NO NO2017054C patent/NO2017054I1/no unknown
- 2017-10-27 HU HUS1700041C patent/HUS000498I2/hu unknown
- 2017-10-31 LT LTPA2017035C patent/LTPA2017035I1/lt unknown

Also Published As

Publication number	Publication date
WO2011018224A1 (en)	2011-02-17
CR20120036A (es)	2012-04-18
IL217753A0 (en)	2012-03-29
HK1245145A1 (zh)	2018-08-24
ZA201200830B (en)	2012-10-31
CA2769674A1 (en)	2011-02-17
CY2017034I1 (el)	2018-02-14
EP2464382B1 (en)	2017-05-03
JP2013501740A (ja)	2013-01-17
KR101425736B1 (ko)	2014-08-01
HUS1700041I1 (hu)	2017-11-28
JP5963013B2 (ja)	2016-08-03
AR077866A1 (es)	2011-09-28
JP2016222673A (ja)	2016-12-28
US20140044705A1 (en)	2014-02-13
UA110096C2 (uk)	2015-11-25
CN107261138A (zh)	2017-10-20
AU2010281866B2 (en)	2016-05-12
RS56146B1 (sr)	2017-11-30
HRP20170972T1 (hr)	2017-09-22
MX355849B (es)	2018-05-02
US20160166688A9 (en)	2016-06-16
BR112012002855A2 (pt)	2016-11-01
SG178324A1 (en)	2012-03-29
JP2015071611A (ja)	2015-04-16
DK2464382T3 (en)	2017-07-17
NO2017054I1 (no)	2017-10-26
MX2012001782A (es)	2012-04-19
MA33469B1 (fr)	2012-07-03
CN102596245A (zh)	2012-07-18
CY1119251T1 (el)	2018-02-14
RU2012109445A (ru)	2013-09-27
EP2464382A1 (en)	2012-06-20
NZ597666A (en)	2013-10-25
TW201110980A (en)	2011-04-01
US20120315268A1 (en)	2012-12-13
CA2769674C (en)	2018-01-23
MY163003A (en)	2017-07-31
LUC00045I2 (pl)	2018-02-26
HUE033531T2 (hu)	2021-12-28
TWI409079B (zh)	2013-09-21
JP5646626B2 (ja)	2014-12-24
SI2464382T1 (sl)	2017-08-31
ES2630158T3 (es)	2017-08-18
US20110165151A1 (en)	2011-07-07
SMT201700329T1 (it)	2017-09-07
LT2464382T (lt)	2017-07-25
PT2464382T (pt)	2017-06-30
CY2017034I2 (el)	2018-02-14
IL217753A (en)	2016-10-31
AU2010281866A1 (en)	2012-02-02
KR20120054068A (ko)	2012-05-29
HUS000498I2 (hu)	2021-03-29
US20150093376A1 (en)	2015-04-02
LUC00045I1 (pl)	2017-11-03
CL2012000391A1 (es)	2012-08-24
LTPA2017035I1 (lt)	2017-11-27

Publication	Publication Date	Title
ZA201200830B (en)	2012-10-31	Combination therapy of an afucosylated cd20 antibody with bendamustine
HRP20190554T1 (hr)	2019-05-03	Kombinacijska terapija s protutumorskim antibiotikom
EP2405937A4 (en)	2012-06-20	CANCER THERAPY USING A COMBINATION OF BENDAMUSTIN AND AN ANTIBODY AGAINST CD20
EP2422846A4 (en)	2012-10-03	CORPUSCULAR RADIATION THERAPY APPARATUS
PL2440287T3 (pl)	2013-12-31	Urządzenie do terapii fotodynamicznej
IL218724A0 (en)	2012-06-28	Endoglin antibodies
GB0916666D0 (en)	2009-11-04	Photodynamic therapy device
EP2618133A4 (en)	2014-12-03	OPTICAL-ELECTRIC FIELD REINFORCING DEVICE
ZA201103790B (en)	2012-08-29	Solid dosage forms of bendamustine
ZA201201038B (en)	2012-10-31	Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone
IL215481A0 (en)	2011-12-29	Improved glucocorticoid therapy
GB0905972D0 (en)	2009-05-20	Antibodies against IL-17BR
GB2471750B (en)	2012-02-08	Radiation therapy device
DK2325510T3 (da)	2013-06-03	Kobling med en ringformet koblingskrop
PL2100692T3 (pl)	2011-11-30	Sposób wytwarzania urządzenia obróbkowego z korpusem z betonu
GB0902916D0 (en)	2009-04-08	Antibody therapy
GB201008945D0 (en)	2010-07-14	An injector
GB0907571D0 (en)	2009-06-10	The reason of all cancer types
TWM385713U (en)	2010-08-01	Light source body structure
GB0921244D0 (en)	2010-01-20	Therapy
GB0914820D0 (en)	2009-09-30	WATerian therapy
GB0903319D0 (en)	2009-04-08	Therapy
GB0903321D0 (en)	2009-04-08	Therapy